180 Life Sciences Provides Update on Correspondence Received from U.K. and U.S. Regulatory Authorities on Pathway for a Therapy That Could Prevent Progression of Early-Stage Dupuytren's Disease
Stock Information for 180 Life Sciences Corp.
Loading
Please wait while we load your information from QuoteMedia.